The study elucidated the potential mechanisms by which RA affects the development of NASH, investigated the effects of RA on glycolysis and the TLR4/activator protein 1 (AP1) pathway in primary liver cells and provided a development for therapeutic interventions for NASH. Here, FOS is linked to metabolic dysfunction-associated steatohepatitis.